Louisiana Accuses Amgen Of Tying Cancer Drugs

Law360, New York (February 21, 2008, 12:00 AM EST) -- The state of Louisiana and its health department have accused biotech company Amgen Inc. of using its monopoly in the market for one type of anti-cancer drug to boost the sales of a second anti-cancer drug through tying, in violation of state antitrust laws.

On Feb. 13, Amgen removed the case, which was initiated in Louisiana state court, to the U.S. District Court for the Eastern District of Louisiana, citing the Class Action Fairness Act.

The complaint requests treble damages and injunctive relief on behalf of...
To view the full article, register now.